博碩士論文 109225008 詳細資訊

本論文永久網址:   


以作者查詢圖書館館藏 以作者查詢臺灣博碩士 以作者查詢全國書目 勘誤回報 、線上人數:27 、訪客IP:3.144.47.100
姓名 施業娟(YEH-CHUAN SHIH)  查詢紙本館藏   畢業系所 統計研究所
論文名稱 根據效用函數建立複合藥之早期臨床試驗設計
(Design of early clinical trial for combined drugs based on utility function)
相關論文
★ 藥物最低有效劑量之無母數鑑別★ 根據貝氏檢定建構的第一期臨床試驗設計
★ 第一期臨床試驗之貝氏調適設計★ 強餘震之即時貝氏預測
★ 鑑別最佳添加藥物劑量的兩階段早期臨床試驗設計★ 臺灣地區地下水品質之統計研究
★ 右設限存活資料之下每日可服劑量之研究★ 集集餘震之統計研究
★ 多群資料下最低有效劑量之聯合鑑別★ 最大餘震規模之統計分析
★ 最大餘震發生時間之統計分析★ 地震預測之統計分析
★ 加權Kaplan-Meier統計量之推廣★ 鑑別藥物最低有效劑量之檢定
★ 餘震序列RJ模型之貝氏分析★ 藥物最低有效劑量之穩健鑑別
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   至系統瀏覽論文 (2025-8-1以後開放)
摘要(中) 本文針對合併兩種藥物治療腫瘤的複合藥進行早期臨床試驗設計,其中可能包含二種化療藥或一種化療藥與一種標靶藥。上述複合藥的毒性會因劑量增加而增強,但是標靶藥的遞增藥效可能在較高的劑量時趨於平穩而呈現高原現象,因此本文建議整合毒性與藥效機率設立效用函數,然後尋找該複合藥合乎毒性要求且具有最高效用的最佳生物劑量組合。本文針對二元毒性與藥效反應提出兩種早期臨床試驗設計,其中一種屬於同時考量毒性與藥效的單階升降劑量設計 (cBOIN12);另一種則為兩階段的升降劑量設計(cUBOIN)。最後本文在多種不同的毒性與藥效機率組合情境之下進行模擬,研究上述複合藥早期臨床試驗設計在選擇最佳生物劑量組合的表現與毒性控管的成效,同時也審視兩種設計的試驗時間。
摘要(英) This thesis considers early clinical trial designs for the combination of two drugs in the treatment of oncology, which may include two chemotherapies or a chemotherapy along with a Molecularly Targeted Agent (MTA). The toxicity of the combined drugs increases with higher doses, but the efficacy of the MTA may plateau at higher doses. Therefore, in this thesis, a utility function that integrates the toxicity and efficacy probabilities is used to find the optimal dose combination (ODC) of the combined drugs, where the ODC meets the toxicity requirements and has the largest utility. Two early clinical trial designs are proposed for binary toxicity and efficacy responses, including a single-stage dose-escalation design (cBOIN12) that considers both toxicity and efficacy simultaneously, and a two-stage dose-escalation design (cUBOIN). Finally, we conduct a simulation study under various combinations of toxicity and efficacy probabilities to investigate the performance of estimating ODC and controlling toxicity as well as the required trial time of the proposed early clinical trial designs for combined drugs.
關鍵字(中) ★ 複合藥
★ 最佳生物劑量組合
★ 早期臨床試驗設計
★ 貝氏方法
★ 模型輔助設計
關鍵字(英) ★ Combined drugs
★ Optimal dose combination
★ Early clinical trial design
★ Bayesian method
★ Model-assisted design
論文目次 摘要 i
Abstract ii
致謝辭 iii
目錄 iv
圖目次 vi
表目次 ix
第一章 研究問題及動機 1
第二章 文獻回顧 4
2.1 單一藥臨床試驗設計 4
2.1.1 BOIN第一期臨床試驗設計 4
2.1.2 BOIN12早期臨床試驗設計 6
2.1.3 UBOIN早期臨床試驗設計 9
2.2 BOIN複合藥第一期臨床試驗設計 12
第三章 複合藥早期臨床試驗設計 14
3.1 符號介紹 14
3.2 單階劑量組合升降設計 16
3.3 兩階劑量組合升降設計 18
第四章 模擬研究 21
4.1 模擬研究設計 21
4.2 模擬研究結果 23
第五章 結論與未來研究 27
參考文獻 29
附錄 31
參考文獻 Dykstra, R.L. and Robertson, T. (1982) An algorithm for isotonic regression for two or more independent variables. The Annals of Statistics; 10:708-716.
Guo, B., Garrett-Mayer, E. and Liu, S. (2021) A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent. Journal of the Royal Statistical Society: Series C Applied Statistics; 70:1210-1229.
Liu, S. and Yuan, Y. (2015) Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C Applied Statistics; 64:507-523.
Lin, R. and Yin, G. (2017) Bayesian optimal interval design for dose finding in drug-combination trials. Statistical Methods in Medical Research; 26:2155-2167.
Lin, R., Zhou, Y., Yan, F., Li, D., Yuan, Y. (2020) BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology; 4:1393-1402.
O′Quigley, J., Pepe, M., Fisher, L. (1990) Continual Reassessment Method: A practical design for phase I clinical trials in cancer. Biometrics; 46:33-48.
Pan, H., Lin, R., Zhou, Y., Yuan, Y. (2020) Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials; 92:105972.
Riviere, M. K., Yuan, Y., Dubois, F., and Zohar, S. (2014) A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics; 13: 247–257.
Riviere, M.K., Yuan, Y., Dubois, F., Zohar, S. (2015) A Bayesian dose-finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. Journal of the Royal Statistical Society: Series C Applied Statistics; 64:215-229.
Shimamura, F., Hamada, C., Matsui, S., and Hirakawa, A. (2018) Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. Journal of Biopharmaceutical Statistics; 28:1025-1037.
Wages, N. A., Conaway, M. R. (2014) Phase I/II adaptive design for drug combination oncology trials. Statistics in Medicine; 33:1990-2003.
Wheeler, G. M., Sweeting, M. J., and Mander, A. P. (2019) A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data. Journal of the Royal Statistical Society: Series C Applied Statistics; 68:309-329.
Yuan, Y. and Yin, G. (2011) Bayesian phase I/II adaptively randomized oncology trials with combined drugs. The Annals of Applied Statistics; 5:924-942.
Zhou, Y., Lee, J.J., Yuan, Y. (2019) A Utility-based Bayesian Optimal Interval (U-BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies. Statistics in Medicine; 38:5299-5316.
黃致杰,「複合藥之早期臨床試驗設計」,國立中央大學,碩士論文,民國111年。
指導教授 陳玉英(Yuh-Ing Chen) 審核日期 2023-7-5
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明